Medicare Enrolled
Dr. Marc Tack, DO
Infectious Disease · Kingston, NY
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Speaking/Promotional
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Tack from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Tack?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Tack
Dr. Marc Tack is an infectious disease specialist in Kingston, NY, with 20 years of NPI registration. Based on federal Medicare data, Dr. Tack performed 131,223 Medicare services across 1,345 unique beneficiaries.
Between the years covered by Open Payments, Dr. Tack received a total of $50,075 from 57 pharmaceutical and/or device companies across 668 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in infectious disease. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Tack is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 0% volume in NY
$50,075 industry payments
Medicare Practice Summary
Medicare Utilization ↗131,223
Medicare services
Top 0% in NY for infectious disease
1,345
Unique beneficiaries
$3
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~6,561 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Daptomycin antibiotic injection | 115,260 | $0 | $0 |
| Dalbavancin injection, 5 mg An injection of the antibiotic dalbavancin, administered in a 5 mg dose. |
10,400 | $12 | $20 |
| Ceftriaxone antibiotic injection This code represents the administration of ceftriaxone sodium, an antibiotic medication. The charge is calculated for every 250 mg of the drug administered. |
1,632 | $0 | $1 |
| Ertapenem sodium injection, 500 mg An injection of ertapenem sodium, an antibiotic medication, administered at a dose of 500 mg. |
1,040 | $10 | $50 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
854 | $57 | $87 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
577 | $68 | $115 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
437 | $104 | $201 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
248 | $25 | $37 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
166 | $150 | $237 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
113 | $74 | $150 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
109 | $103 | $165 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
72 | $108 | $163 |
| Hospital follow-up visit, low complexity Follow-up hospital visit for an established patient with straightforward or low-level medical decision making. The visit requires at least 25 minutes of time spent on the day of service. |
72 | $43 | $63 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
60 | $6 | $20 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
42 | $138 | $260 |
| Flu vaccine administration This procedure involves the administration of the influenza virus vaccine. It covers the process of delivering the vaccine to the patient. |
34 | $29 | $30 |
| Flu vaccine, high-dose High-dose seasonal influenza vaccine for adults aged 65 and older. Contains four times the antigen of standard-dose flu vaccines (60 mcg per strain), split-virus formulation, preservative-free, single-dose syringe. |
30 | $70 | $80 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
27 | $146 | $300 |
| New patient office visit, complex (60-74 min) | 26 | $184 | $375 |
| Annual wellness visit, follow-up A follow-up annual wellness visit that includes a personalized prevention plan of service. |
13 | $137 | $136 |
| COVID-19 amplified DNA/RNA probe detection A laboratory test that uses amplified DNA or RNA probes to detect the presence of severe acute respiratory syndrome coronavirus 2 (COVID-19) antigen. |
11 | $46 | $65 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
0.8% high complexity
97.8% medium
1.3% routine
Industry Payment Transparency
Open Payments through 2024 ↗$50,075
Total received (2018-2024)
Avg $7,154/year across 7 years
Top 5% in NY for infectious disease
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
57
Companies
668
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$23,403 (46.7%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$16,207 (32.4%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$10,465 (20.9%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$4,428
2023
$11,451
2022
$1,558
2021
$2,459
2020
$4,308
2019
$24,098
2018
$1,774
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Shionogi Inc
$2,964
Gilead Sciences, Inc.
$314
ABBVIE INC.
$196
ViiV Healthcare Company
$193
Merck Sharp & Dohme LLC
$185
Amgen Inc.
$123
PFIZER INC.
$89
Insmed, Inc.
$75
SANOFI-AVENTIS U.S. LLC
$55
Paratek Pharmaceuticals, Inc.
$55
Otsuka America Pharmaceutical, Inc.
$46
Dexcom, Inc.
$24
Inspire Medical Systems, Inc.
$23
EMD Serono, Inc.
$18
GlaxoSmithKline, LLC.
$18
Phathom Pharmaceuticals, Inc.
$18
Lilly USA, LLC
$17
Novo Nordisk Inc
$16
Top 3 companies account for 78.4% of 2024 payments
All-time payments by company (2018-2024) ›
Insmed, Inc.
$36,606
Shionogi Inc
$2,964
ViiV Healthcare Company
$2,026
Gilead Sciences, Inc.
$1,181
Merck Sharp & Dohme Corporation
$812
Merck Sharp & Dohme LLC
$564
Amgen Inc.
$542
PFIZER INC.
$496
Horizon Therapeutics plc
$444
GlaxoSmithKline, LLC.
$419
Paratek Pharmaceuticals, Inc.
$401
Janssen Biotech, Inc.
$384
AstraZeneca Pharmaceuticals LP
$377
ABBVIE INC.
$341
AbbVie Inc.
$315
COMSORT, Inc
$200
Allergan Inc.
$170
Janssen Pharmaceuticals, Inc
$123
Endo Pharmaceuticals Inc.
$122
EMD Serono, Inc.
$99
TETRAPHASE PHARMACEUTICALS, INC.
$96
Harmony Biosciences LLC
$93
Astellas Pharma US Inc
$84
Melinta Therapeutics, Inc.
$81
Melinta Therapeutics, LLC
$74
Allergan, Inc.
$73
Takeda Pharmaceuticals U.S.A., Inc.
$72
Ferring Pharmaceuticals Inc.
$71
Theravance Biopharma, Inc.
$71
Lilly USA, LLC
$65
Novo Nordisk Inc
$59
SANOFI-AVENTIS U.S. LLC
$55
Regeneron Healthcare Solutions, Inc.
$52
Otsuka America Pharmaceutical, Inc.
$46
Boston Scientific Corporation
$45
Dexcom, Inc.
$41
Salix Pharmaceuticals, a division of Bausch Health US, LLC
$33
Novartis Pharmaceuticals Corporation
$30
Celgene Corporation
$29
Theratechnologies Inc.
$28
Shire North American Group Inc
$24
AbbVie, Inc.
$23
Inspire Medical Systems, Inc.
$23
Kiniksa Pharmaceuticals, Ltd.
$20
Grifols USA, LLC
$20
Sanofi Pasteur Inc.
$19
Bayer HealthCare Pharmaceuticals Inc.
$18
Phathom Pharmaceuticals, Inc.
$18
Horizon Pharma plc
$18
AngioDynamics, Inc.
$16
SOBI, INC
$16
Edwards Lifesciences Corporation
$16
VBI Vaccines (Delaware) Inc.
$14
Nabriva Therapeutics, plc
$14
Medtronic, Inc.
$14
Abbott Laboratories
$12
Exsomed Holding Company LLC
$9
Top 3 companies account for 83.1% of all-time payments
Associated products mentioned in payments ›
ABILIFY ASIMTUFII · AMJEVITA · ANORO · AREXVY · AVYCAZ · Aimovig · Arcalyst · Arikayce · Baxdela · CABENUVA · CHANTIX · CRESEMBA · CUVITRU · DALVANCE · DIFICID · DOVATO · Dexcom G6 Transmitter · EGRIFTA · ELIQUIS · EMGALITY · ENTRESTO · EVENITY · EVUSHELD · Edwards SAPIEN 3 Transcatheter Heart Valve · Enbrel · FARXIGA · FASENRA · FORTEO · Fetroja · FreeStyle Libre · GARDASIL · GARDASIL 9 · GLASSIA · Gamunex-C · HYQVIA · INFLECTRA · INSPIRE · INTERSTIM · INate · ISENTRESS · JANUVIA · JULUCA · KEVZARA · KEVZARA SARILUMAB INJECTION · KINERET · KRYSTEXXA · Kerendia · MENACTRA · Mavyret · NUCALA · NUZYRA · OCTAGAM IMMUNE GLOBULIN (HUMAN) · Orbactiv · Otezla · Ozempic · PANZYGA · PIFELTRO · PNEUMOVAX 23 · PREVNAR - 13 · PREVNAR 20 · PREVYMIS · PREZCOBIX · PREZISTA · PreHevbrio · Prolia · REBYOTA · RENFLEXIS · REXULTI · RUKOBIA · SAPHNELO · SEROSTIM · SHINGRIX · SIMPONI · SIMPONI ARIA · SIVEXTRO · STELARA · SYMTUZA · Serostim · Symtuza · TALTZ · TRELEGY ELLIPTA · TRIUMEQ · TZIELD · UBRELVY · VIBATIV · VOQUEZNA · VRAYLAR · Vabomere · WAKIX · XARELTO · XERAVA · XIAFLEX · XIFAXAN · Xenleta · Xerava · ZERBAXA · ZINPLAVA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (47%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in infectious disease and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 5% for infectious disease in NY.
Geographic Context
Infectious diseases within 10 mi
8
Per 100K population
4.4
County median income
$81,804
Nearest hospital
HEALTHALLIANCE HOSPITAL MARYS AVENUE CAMPUS
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Tack is a mixed practice specialist, with above-average Medicare volume (top 0% in NY), with speaking/promotional industry engagement in the top 5% of NY peers, with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Tack experienced with daptomycin antibiotic injection?
Based on Medicare claims data, Dr. Tack performed 115,260 daptomycin antibiotic injection services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Tack receive payments from pharmaceutical companies?
Yes. Dr. Tack received a total of $50,075 from 57 companies across 668 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Tack's costs compare to other infectious diseases in Kingston?
Dr. Tack's average Medicare payment per service is $3. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Tack) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Infectious Diseases in Kingston
Browse infectious diseases in Kingston ranked by procedure volume and transparency data.
Highest volume
Top Infectious Diseases in NY
Infectious diseases ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Infectious Diseases in NY
Which NY infectious diseases receive the most from drug and device companies.
By company
Insmed, Inc. Payments to Doctors
See all physicians who received payments from Insmed, Inc.
By company
Shionogi Inc Payments to Doctors
See all physicians who received payments from Shionogi Inc.
By company
ViiV Healthcare Company Payments to Doctors
See all physicians who received payments from ViiV Healthcare Company.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology